前列腺癌组织bcl-2、p53、P504S及34βE12蛋白的表达水平

Expression of bcl-2,p53,P504S and 34βE12 Proteins in Prostatic Carcinoma

目的研究前列腺癌(prostate carcinoma,Pca)组织bcl-2、p53、P504S及34βE12蛋白的表达水平,及其与前列腺癌发生发展的关系。方法应用SP法,检测54例前列腺癌标本的bcl-2、p53、P504S及34βE12蛋白的表达水平;并与20例良性前列腺增生标本进行对照。结果前列腺癌组织中bcl-2及p53蛋白表达的阳性率分别为44.4%和33.3%,均高于良性前列腺增生的阳性率(25.0%和15.0%),但差异无统计学意义(P>0.05)。在前列腺癌中,低分化组bcl-2的表达水平明显高于高及中分化组(P<0.05),临床分期D期明显高于B及C期(P<0.05);p53的表达水平在上述各组及各期之间均无统计学差异(P>0.05);P504S在54例前列腺癌均呈阳性表达,相反34βE12均呈阴性表达。结论在前列腺癌鉴别诊断中,P504S能区别良性腺体和癌,bcl-2及P504S蛋白在前列腺癌的异常表达,可能与前列腺癌的发生发展及预后有关,检测bcl-2、P504S及34βE12蛋白表达水平对前列腺癌的诊断及鉴别诊断具有重要价值。

Objective To study the expression of bcl-2,p53,P504S and 34βE12 proteins in patients with prostatic carcinoma and the relationship between these gene products and the pathogenesis of prostatic carcinoma.Methods Expression of bcl-2,p53,P504S and 34βE12 proteins in fifty-four cases of prostatic carcinoma and twenty cases of benign hyperplasia of prostate was determined with immunohistochemical SP assay.Results It was found that positive rates of bcl-2 and p53 in prostatic carcinoma were 44.4% and 33.3% respectively,both were not significantly higher than those in benign hyperplasia of prostate statistically,but a tendency of their increasing expression in prostatic carcinoma could be seen.The expression of bcl-2 in the group of poor differentiated was significantly higher than that in the well-differentiated group(P<0.05).When compared in terms of clinical stages,it was observed that bcl-2 expression at stage D was significantly higher than that at stage B or C(P<0.05).There existed a tendency of increase in p53 expression in prostatic carcinoma,but it was not significantly higher than that in benign hyperplasia of prostate.The tumor cells displayed positive reaction for P504S and negative for 34βE12.P504S can be used to differentiate the benign prostate gland from the prostatic carcinoma.Conclusion It is suggested that bcl-2 and P504S protein expressions increase in prostate carcinoma and is,to some extent,involved in the pathogenesis and development of the disease.It is important to use immunohistochemical staining for bcl-2,P504S and 34βE12 protein in the pathologic diagnosis of prostatic carcinoma.